CABOPRE: Evaluating Perioperative Cabozantinib’s Efficacy and Biomarkers for Cytoreductive Nephrectomy in Advanced Renal Cell Carcinoma

Background/Objectives: Despite advances in metastatic renal cell carcinoma (mRCC), long-term survival is poor and biomarkers are lacking. Optimal integration of cytoreductive nephrectomy (CN) in the current era remains controversial. CABOPRE, the first phase II trial assessing perioperative cabozantinib in mRCC patients eligible for CN, aimed to determine its effects in this setting, integrating tumor outcomes with molecular profiling.